Navigation Links
DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
Date:8/5/2013

been selected.
  • Relday (Risperidone Program). In January 2013, Zogenix (our licensee) announced positive single-dose pharmacokinetic (PK) results from a Phase 1 clinical trial of Relday. According to Zogenix, adverse events in the Phase 1 trial in patients diagnosed with schizophrenia were generally mild to moderate and consistent with other risperidone products. The Phase 1 clinical trial for Relday was conducted as a single-center, open-label, safety and PK trial of 30 patients with chronic, stable schizophrenia or schizoaffective disorder. Per Zogenix, based on the favorable safety and PK profile demonstrated with the 25 mg and 50 mg once-monthly doses tested in the Phase 1 trial, Zogenix extended the study to include a 100 mg dose of the same formulation. In May 2013, Zogenix announced positive results with the 100 mg arm, demonstrating dose proportionality across the full dose range that would be anticipated to be used in clinical practice. According to Zogenix, the positive results from this study extension positions Zogenix to begin a multi-dose clinical trial, which would provide the required steady-state pharmacokinetic and safety data prior to initiating Phase 3 development studies, subject to Zogenix's ability to secure a development and commercialization partner prior to initiation of the multi-dose trial.
    Relday is a proprietary, long-acting, once-monthly subcutaneous injectable formulation of risperidone using DURECT's SABER controlled-release formulation technology. An existing long-acting injectable risperidone product, which achieved $1.4 billion in global net sales in 2012, requires twice-monthly, intramuscular injections and drug reconstitution prior to use.
  • Feasibility Projects and Other Activities. During the second quarter of 2013, we continued work on several feasibility projects as a means of demonstrating that our technologies can achieve the drug delivery objectives set forth by
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    2. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
    3. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
    4. DURECT to Participate in Upcoming Healthcare Conferences
    5. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
    6. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
    7. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
    8. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
    9. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
    10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    11. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
    (Date:9/18/2014)... 2014 According to the ... Intravascular Systems- Warming & Cooling), Application (Acute & ... Anesthesiologist, Nursing & Paramedical Staff) - Global Forecasts ... studies the global Temperature Management Market over the ... is expected to reach $2.5 Billion by 2019 ...
    (Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... PTCA Balloon Market Investment Report, 2014-2016" report to ... indispensable medical device in percutaneous coronary intervention (PCI), serves ... also as a device for pre-/post-stent dilatations. Therefore, the ... that of PCI. As national economy develops ...
    Breaking Medicine Technology:MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
    ... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
    ... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
    Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
    (Date:9/19/2014)... Washington, D.C. (PRWEB) September 19, 2014 ... in Madison County Circuit Court (case 14-L-1175), following a ... Carole Owen is suing DePuy Orthopaedics Inc. and ... product was defective. Flood Law Group, a nationally known ... and has been following developments in litigation involving defective ...
    (Date:9/19/2014)... 19, 2014 Getting together with friends is ... LunaDress understands the desire to look graceful without ... proudly released its new range of fashionable prom dresses. Apart ... appreciation to customers throughout the world. Now, all the global ... ordering prom outfits on its website. , The company’s ...
    (Date:9/18/2014)... When Mary Ann Thompson and Mathieu Nikel decided it ... Bali, Indonesia with their son, Isaac, said there was only one ... Mercy College in 2001 when Thompson was an undergraduate student and ... student at the time, was French and so she asked him. ... the United States when she was 7 years old. Nikel ...
    (Date:9/18/2014)... experts around the world have issued a plea to ... out high quality research and clinical trials for advanced ... and for which there are many unanswered questions. , ... of advanced breast cancer, published simultaneously in the leading ... of Oncology [1] today (Friday), the experts say ...
    (Date:9/18/2014)... A jacket is a hip- or waist-length garment ... and fastens in the front or slightly on the ... insulating than a coat, which is outerwear. Some jackets ... Fecbek, a well-known clothing manufacturer and retailer, has delightedly ... these items are offered at extremely low prices? ...
    Breaking Medicine News(10 mins):Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2Health News:With New Semester Under Way, LunaDress Unveils The Most Fashionable Prom Dresses 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Experts issue plea for better research and education for advanced breast cancer 2Health News:Experts issue plea for better research and education for advanced breast cancer 3Health News:Experts issue plea for better research and education for advanced breast cancer 4Health News:Experts issue plea for better research and education for advanced breast cancer 5Health News:Cool Jackets Are For Sale At Fecbek.com 2
    ... Holdings,Inc. (NYSE: PAY ) today announced ... with Secure EDI,s state-of-the-art platform to consolidate,patient payments ... Secure EDI is a recognized market ... dental and institutional providers. The,company also creates seamless ...
    ... Annual Basic and Diluted Net Loss per Share of $1.87- ... or $4.77 per Diluted ShareSILVER SPRING, Md., Feb. 17 ... its financial results for the fourth quarter and year ended ... for 2008 grew in excess of 30% for the seventh ...
    ... extended as unlisted warrants to May 12, 2009 -BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced ... the up to 8,203,334 common share purchase warrants issued ... March, 2007. 7,676,554 of these warrants, currently listed for ...
    ... FLORHAM PARK, N.J., Feb. 17 Shionogi & Co, ... velneperit, a novel neuropeptide Y (NPY) Y5 receptor antagonist ... of demonstrating a statistically significant reduction in body weight. ... the NPY Y5 receptor as a target for obesity ...
    ... 17 PAREXEL Consulting, a business unit ... leading global consultancy serving the biopharmaceutical and medical device ... of Principal Consultant in its European Product Development Practice. ... Sweden,s Medical Products Agency (MPA), will advise clients on ...
    ... N.Y., Feb. 17 New paintbrush makes painting ... ArroWorthy Co. NY, is designed to match the ... handle allows a variety of gripping areas for ... incorporated for on job resting or storage. White ...
    Cached Medicine News:Health News:Secure EDI Integrates VeriFone IPCharge in Real Time Patient Payment and Claims Processing Solutions Suite 2Health News:Secure EDI Integrates VeriFone IPCharge in Real Time Patient Payment and Claims Processing Solutions Suite 3Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 2Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 3Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 4Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 5Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 6Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 7Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 8Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 9Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 10Health News:Bioniche Warrants' Expiration Date to be Extended 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 3Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 4Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 5Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 6Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 2Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 3Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 4Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 5Health News:Efficient and Comfortable, the Right Brush(R) is the First Revolution in Painting Since the Roller 2Health News:Efficient and Comfortable, the Right Brush(R) is the First Revolution in Painting Since the Roller 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: